SANGUINE CORPORATION
101 EAST GREEN STREET. SUITE 11 PASADENA, CALIFORNIA 91105
____________
PHONE 626-405-0079
FAX 626-405-1041
NEWS EVENT
Pasadena, California
April 19, 2000
News Event:
Pasadena, Calif - Sanguine Corporation (OTC BB:SGNC) has signed a Letter of Engagement with a New York based Investment Banking Firm to conduct a private offering of their shares to U.S. and international institutional investors.
This funding will be applied to the cost of the animal trials for PHER-02, our synthetic red blood cell, required by the Food and Drug Administration (FDA).
Sanguine Corporation Is- also arranging a bridge loan to cover administrative expenses until this private offering is completed in 3 to 4 weeks.
Notice: This news release contains and oral statements made from time to time by company representatives concerning the information contained herein may contain, so-called "forward-looking statements." These statements can be identified with introductory words such as "expects," "Plans," "will," "estimates," forecasts," "projects," or words or similar meaning and Any the fact that they do relate strictly to historical or current facts.
Forward-looking statements frequently are used in discussing the company's growth strategy, operating and financial goals regulatory submissions and approvals, and development programs.
Many factors may cause actual results to differ from the company's forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.
This news release shall not be deemed to be an offering for these securities.
Contact: Sanguine Corp., Pasadena, CA
Thomas C. Drees
626/405-0079
Fax: 626/405-1041 |
